LP422971-4
Ravulizumab
Active
Description
Ravulizumab is a complement C5 inhibitor that is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Its mechanism of action is binding to the C5 protein, which prevents formation of the complement C5b-9 complex. PMID: 30767127 Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- Ravulizumab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2021-03-26
- Construct for LOINC Short Name
- Ravulizumab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP422971-4
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| it-IT | Italian (Italy) | Ravulizumab |
| nl-NL | Dutch (Netherlands) | ravulizumab |
| es-ES | Spanish (Spain) | Ravulizumab |
| zh-CN | Chinese (China) | 雷夫利珠单抗 Synonyms: Ultomiris; |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright